Latest Headlines from Nourish | The Nourish Mission

Weekly insulin option awaits MHRA decision

What's happened

Nice has approved a weekly insulin to reduce injections from 365 to 52, but MHRA approval is pending. The treatment—Onswik, by Eli Lilly—could improve daily life for patients who rely on carers or face dexterity challenges. NHS readiness hinges on regulatory licensing and clear rollout guidelines.

What's behind the headline?

Analysis

  • This update signals a potential shift in diabetes management, pending MHRA licensing.

  • The central question is access: how quickly the NHS can license, fund, and train staff to support a weekly regimen.

  • The policy promises greater flexibility for patients with care needs, but raises questions about equity and implementation across the UK.

  • What readers should watch:

    • MHRA decision timeline and any conditions attached to rollout
    • NHS implementation guidance and clinician training needs
    • How carers and patients with dexterity challenges prepare for transition

How we got here

Nice has issued final guidance recommending a weekly insulin (Onswik/efsitora alfa) as a potentially transformative option for type 2 diabetes management. MHRA licensing is still required before NHS rollout, with England following Nice guidance and Wales often aligning.

Our analysis

The Independent reports NICE has approved the weekly insulin; BBC Business notes the MHRA ruling is awaited and highlights patient groups like Diabetes UK. Health officials emphasize rigorous decision-making balancing patient benefit with NHS funding. Guardian-style quotes from NHS England and Diabetes UK officials cited in the Independent and BBC articles.

Go deeper

  • When will the MHRA issue a ruling on Onswik?
  • How will NHS England plan staff training for weekly injections?
  • What costs are anticipated for NHS rollout and will access be equitable?

More on these topics


Latest Headlines from Nourish | The Nourish Mission